Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

Blood (2012) 120 (21): 135.

https://doi.org/10.1182/blood.V120.21.135.135

Published: 2012

Journal Articles

A Recurrent Pattern of Acquired Genomic Abnormalities In Myelodysplasia and Leukemia of Fanconi Anemia Includes Cryptic RUNX1/AML1 abnormalities

Blood (2010) 116 (21): 975.

https://doi.org/10.1182/blood.V116.21.975.975

Published: 2010

Journal Articles

Interactions Between Total Nucleated and CD34 Cell Dose and Their Impact on Outcomes After Single and Double Unrelated Cord Blood Transplantation for Patients with Hematological Malignancies. An Analysis on Behalf of Societe' Française De Greffe De Moelle Et Therapie Cellulaire (SFGM-TC) and Eurocord

Mauricette Michallet, Renato L.G. Cunha, Gérard Michel, Gérard Socié, Mohamad Mohty, Bernard Rio, MD, Didier Blaise, MD, Anne Sirvent, MD, Reza Tabrizzi, Pierre Bordigoni, Eric Deconinck, Ibrahim Yakoubagha, Jean-François Rossi, Natacha Maillard, Mohamad Sobh, Federico Garnier, MD, Annalisa Ruggeri, MD, Eliane Gluckman, MD, Vanderson Rocha, MD, PhD

Blood (2010) 116 (21): 361.

https://doi.org/10.1182/blood.V116.21.361.361

Published: 2010

Journal Articles

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 4188.

https://doi.org/10.1182/blood.V116.21.4188.4188

Published: 2010

Journal Articles

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Blood (2008) 112 (11): 10.

https://doi.org/10.1182/blood.V112.11.10.10

Published: 2008

Journal Articles

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Andre Baruchel, MD, Marie-Françoise Auclerc, MD, Yves Perel, MD, Françoise Mechinaud, MD, Anne Auvrignon, MD, Claudine Schmitt, MD, Christophe Piguet, MD, Odile Lejars, MD, Christian Berthou, MD, François Demeocq, MD, Pascale Schneider, MD, Virginie Gandemer, MD, Gérard Michel, MD, Jean-Michel Cayuela, Pharm D, Thierry Leblanc, MD, Guy Leverger, MD, the FRALLE Group

Blood (2006) 108 (11): 1852.

https://doi.org/10.1182/blood.V108.11.1852.1852

Published: 2006

Journal Articles

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

Christine Formisano-Tréziny, Fabienne Hermitte, Benoît Quilichini, Hervé Chambost, Gérard Michel, Jean Gabert

Blood (2006) 108 (11): 4275.

https://doi.org/10.1182/blood.V108.11.4275.4275

Published: 2006

Journal Articles

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

Helene Esperou, MD, Bénédicte Neven, MD, Karima Yakouben, MD, Claire Galambrun, MD, Françoise Méchinaud, MD, Catherine Paillard, MD, Pierre Bordigoni, MD, Hamadi Zouabi, MD, Laurent Nguyen, PharD, Gérard Michel, MD, Gilles Vassal, MD PhD

Blood (2006) 108 (11): 5131.

https://doi.org/10.1182/blood.V108.11.5131.5131

Published: 2006

Journal Articles

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

André Baruchel, MD, Sylvie Chevret, MD, PhD, Anne Auvrignon, MD, Paola Ballerini, MD, PhD, Gérard Michel, MD, Jean Gabert, MD, PhD, Christiane Vermylen, MD, Yves Perel, MD, Chrystèle Bilhou-Nabera, MD, Odile Lejars, MD, Claudine Schmitt, MD, Pierre Jonveaux, MD, PhD, Jean Soulier, MD, PhD, Jacqueline Vandenaker, MD, Marie-Françoise Auclerc, MD, Thierry Leblanc, MD, Guy Leverger, MD, for the FRALLE Group

Blood (2005) 106 (11): 1441.

https://doi.org/10.1182/blood.V106.11.1441.1441

Published: 2005

Journal Articles

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

Gilles Vassal, MD, PhD, Hélène Esperou, MD, Dominique Valteau-Couanet, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Laurent Nguyen, Pharm D, Gérard Michel, MD

Blood (2005) 106 (11): 5200.

https://doi.org/10.1182/blood.V106.11.5200.5200

Published: 2005

Journal Articles

Cerebral Thromboses during Treatment of Childhood Acute Lymphoblastic Leukaemia.

Brigitte Pautard, Julie Micheli, Marie-Françoise Auclerc, Valérie Li Thiao Te, Thierry Leblanc, Barbara Horle, Judith Landman Parker, Claudine Schmitt, Gérard Michel, Pascale Schneider, Geneviève Margueritte, Anne Notz, Virginie Gandemer, Guy Leverger, André Baruchel

Blood (2005) 106 (11): 876.

https://doi.org/10.1182/blood.V106.11.876.876

Published: 2005

Journal Articles

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Gérard Michel, MD, Dominique Valteau-Couanet, MD, Hélène Esperou, MD, Jean Claude Gentet, MD, François Doz, MD, Françoise Méchinaud, MD, Claire Galambrun, MD, Alain Fischer, MD, Hamadi Zouabi, MD, Christian Puozzo, PhD, Gilles Vassal, MD, PhD

Blood (2005) 106 (11): 1758.

https://doi.org/10.1182/blood.V106.11.1758.1758

Published: 2005

Journal Articles

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1952.

https://doi.org/10.1182/blood.V104.11.1952.1952

Published: 2004

Journal Articles

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1105.

https://doi.org/10.1182/blood.V104.11.1105.1105

Published: 2004

Journal Articles

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia

Blood (2001) 97 (10): 2962–2971.

https://doi.org/10.1182/blood.V97.10.2962

Published: 2001

NARROW

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

A Recurrent Pattern of Acquired Genomic Abnormalities In Myelodysplasia and Leukemia of Fanconi Anemia Includes Cryptic RUNX1/AML1 abnormalities

Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

A 3′ RACE-PCR Method of Identification of Unknown MLL Gene Partner and Break-Point at RNA Level.

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation.

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.

Cerebral Thromboses during Treatment of Childhood Acute Lymphoblastic Leukaemia.

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes.

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only